Junk Fine But Bewar...
Health Care: Drugs
XOMA Corp (XOMA: NASDAQ)
$3.64 -0.20 | -5.21%
06/19/13 - 04:00 PM ET
Growth Rates
| GROWTH RATES |
|---|
| REVENUE (Trailing 12 Quarters) |
| EARNINGS PER SHARE (Trailing 12 Quarters) |
| DIVIDENDS (Trailing 12 Quarters) |
Portfolios with XOMA
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks With Big Insider Buy...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- Usersuresh45
- Userdd
- ContributorStocks Under-$10 Setting Up...
- Userconsidering
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
Latest XOMA Headlines from TheStreet
- XOMA Announces Clinical Study Investigating Gevokizumab In Patients With Non-Infectious Anterior Scleritis Has Opened For Enrollment At The National Eye Institute 04.10.13 | 08:04 am
- 8 Stocks Under $5 Seeing Institutional And Insider Buying 04.02.13 | 03:04 pm
- 7 Biotechnology Stocks With Insider Buying Activity 03.20.13 | 10:03 am
- XOMA Appoints Tom Klein To Newly Created Position Of Chief Commercial Officer 03.18.13 | 01:03 pm
- EZChip: My Struggling Core Holding May See Better Days 03.16.13 | 07:03 am
- XOMA Reports 2012 Operational Highlights And Fourth Quarter And Full-Year Financial Results 03.12.13 | 04:03 pm
- XOMA Announces Fourth Quarter And Full-Year Financial Results Conference Call 03.04.13 | 01:03 pm
- 5 Stocks Under $10 Set to Soar 02.28.13 | 01:02 pm
- XOMA To Present At Upcoming Investor Conferences 02.21.13 | 09:02 am
- XOMA Announces Encouraging Interim Results From Gevokizumab Phase 2 Study For Moderate To Severe Acne Vulgaris 01.07.13 | 08:01 am
Press Releases for XOMA
- CMC Biologics Acquires XOMA's Bay Area Manufacturing Facility - PR Newswire 07.31.12 | 08:07 am
Partner Headlines for XOMA
- XOMA Begins Pilot Trial Evaluating Gevokizumab - Benzinga 06.13.13 | 09:06 am
- Positive Data on XOMA Candidate - Analyst Blog - Zacks 11.26.12 | 06:11 pm
- UPDATE: Credit Suisse Initiates XOMA Corporation at Outperform on Upside Potential - Benzinga 11.13.12 | 01:11 pm
- XOMA Announces Servier Has Initiated Phase 3 Gevokizumab Trial in Patients With Behcet's Uveitis - Benzinga 09.27.12 | 01:09 pm
- Orphan Status for XOMA's Candidate - Analyst Blog - NASDAQ 08.23.12 | 07:08 pm
- Loss at XOMA Wider Than Expected - Analyst Blog - Zacks 03.20.12 | 10:03 am
- Noteworthy Institutional 5% Ownership Filings Last Week - Seeking Alpha 03.19.12 | 09:03 am
- Xoma's New Plans Bring Hesitant Hope - Seeking Alpha 01.25.12 | 09:01 am
- XOMA Will Move Its Corporate Domicile to Delaware - Benzinga 12.30.11 | 04:12 pm
- XOMA CEO Engle Resigns - Benzinga 08.31.11 | 04:08 pm
